Fig. 5

Linking PANoptosis Enrichment to Cellular Neoplastic Heterogeneity and Aggressiveness. A-B Comparison of PANoScore between the low and high mRNA expression-based stemness index (mRNAsi) groups in GBM. C-D Distribution of PANoScore among different transcriptional subtypes: proneural (PN), classical (CL), and mesenchymal (MS). E Single-cell RNA sequencing (scRNA-seq) analysis showing the PANoScore distribution across astrocyte-like (AC-like), mesenchymal-like (MES-like), neural-progenitor-like (NPC-like), and oligodendrocyte-progenitor-like (OPC-like) cellular states. F Comparison of the PANoScore among AC-like, MES-like, NPC-like, and OPC-like cells. G Proportion of AC-like, MES-like, NPC-like, and OPC-like cells in high and low PANoScore groups. H Oncoplot displaying mutational differences between the high and low PANoScore groups. I-J Estimated half maximal inhibitory concentration (IC50) of EGFR-targeted drugs (gefitinib and erlotinib) compared between the low and high PANoScore groups. K-L Gene set enrichment analysis (GSEA) showing enrichment of immune-related pathways in high-PANoScore GBM samples